Arax Advisory Partners’s Maze Therapeutics MAZE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.08K Buy
334
+180
+117% +$5K ﹤0.01% 4458
2026
Q2
$4.6K Buy
+154
New +$4.04K ﹤0.01% 4618
2025
Q4
– Sell
-307
Closed -$7.96K – 4620
2025
Q3
$7.96K Buy
+307
New +$5.18K ﹤0.01% 2692

Other funds holding MAZE

Arax Advisory Partners's MAZE Position: Q3 2026 in Review

Arax Advisory Partners increased its Maze Therapeutics (MAZE) stake by 117% in Q3 2026, buying an estimated $5K and bringing the position to 334 shares worth $9.08K. The position accounts for ﹤0.01% of the portfolio, ranked #4458.

Arax Advisory Partners first reported a position in MAZE in Q3 2025 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Arax Advisory Partners held 334 shares of Maze Therapeutics worth $9.08K as of Q3 2026.
  • Arax Advisory Partners bought 180 Maze Therapeutics shares in Q3 2026, an estimated $5K.
  • Maze Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #4458 holding.
  • Arax Advisory Partners first reported a position in Maze Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.